The rest of this story is for members
The rest is for members
The story continues: the full timeline, the transaction ranges, and the names the forms carry.
Premium comes through the Telegram channel. Already have a code? Sign in to activate it.
PremiumOTLK
BTIG identifies almost 184% upside in Outlook Therapeutics after FDA approval
BTIG upgraded Outlook Therapeutics stock to 'Buy' with a price target of $4.00, following FDA approval for the drug LYTENAVA, the first ophthalmic bevacizumab formulation approved for the treatment of wet macular degeneration.
Related Stories
Three analysts and AI industry experts re-rate Nvidia - we've compiled everything important for you to know
AnalystsNVDA1d ago5 min read
KURA: buy recommendation from analysts
PremiumAnalystsKURA1w ago1 min read
Onds: Oppenheimer raises price target
PremiumAnalystsONDS1w ago1 min read